AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38517479 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision-Making Engagement Preferences
Number of subjects: 0
Study 38517612 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth devices
Number of subjects: 107
Study 38517612 — intervention group
Group type: COMPARATOR
Intervention: Control (no mHealth devices)
Number of subjects: 107
Study 38517907 — intervention group
Group type: EXPERIMENTAL
Intervention: albendazole-ivermectin treatment
Number of subjects: 87
Study 38517907 — intervention group
Group type: COMPARATOR
Intervention: albendazole treatment
Number of subjects: 87
Study 38517907 — intervention group
Group type: EXPERIMENTAL
Intervention: hookworm treatment (both arms)
Number of subjects: 87
Study 38518104 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP array analysis
Number of subjects: 317
Study 38518263 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-load, high-repetition resistance exercise (LLHR RE)
Number of subjects: 24
Study 38518263 — intervention group
Group type: COMPARATOR
Intervention: Moderate-intensity continuous exercise (MIC)
Number of subjects: 24
Study 38518434 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) 3 mg/kg b.i.d. for weight < 10 kg
Number of subjects: 0
Study 38518434 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) 2.5 mg/kg b.i.d. for weight ≥ 10 kg and < 20 kg
Number of subjects: 0
Study 38518434 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) 2 mg/kg b.i.d. for weight ≥ 20 kg
Number of subjects: 0
Study 38518434 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) 2-3 mg/kg b.i.d.
Number of subjects: 0
Study 38518434 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) 1 mg/kg b.i.d.
Number of subjects: 0
Study 38518479 — intervention group
Group type: EXPERIMENTAL
Intervention: Online group-based Acceptance and Commitment Therapy (ACT), 8 sessions as online group therapy.
Number of subjects: 53
Study 38518479 — intervention group
Group type: COMPARATOR
Intervention: Control group (no application made by researchers).
Number of subjects: 53
Study 38518479 — intervention group
Group type: EXPERIMENTAL
Intervention: Online group-based ACT.
Number of subjects: 53
Study 38518549 — intervention group
Group type: EXPERIMENTAL
Intervention: Domatinostat 200 mg twice daily (BD) plus avelumab 10 mg/kg every 2 weeks (2qw)
Number of subjects: 40
Study 38518549 — intervention group
Group type: EXPERIMENTAL
Intervention: Domatinostat 200 mg BD plus avelumab 10 mg/kg 2qw
Number of subjects: 40
Study 38518789 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1273.214 primary series (25 μg)
Number of subjects: 718
Study 38518789 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1273.214 booster dose (10 μg)
Number of subjects: 718
Study 38518789 — intervention group
Group type: COMPARATOR
Intervention: mRNA-1273 primary series (historical comparator)
Number of subjects: 718
Study 38518789 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1273.214 primary series and booster dose
Number of subjects: 718
Study 38518848 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet rich in monounsaturated fatty acids (MUFAs) (SFA: 7.1%E; MUFA: 20.7%E)
Number of subjects: 18
Study 38518848 — intervention group
Group type: COMPARATOR
Intervention: Diet rich in saturated fatty acids (SFAs) (SFA: 13.4%E; MUFA: 14.4%E)
Number of subjects: 18
Study 38519053 — intervention group
Group type: EXPERIMENTAL
Intervention: GD2BATs (anti-CD3×anti-GD2 bispecific antibody armed T cells)
Number of subjects: 9
Study 38519053 — intervention group
Group type: EXPERIMENTAL
Intervention: GD2BATs
Number of subjects: 9
Study 38519055 — intervention group
Group type: EXPERIMENTAL
Intervention: Odronextamab monotherapy
Number of subjects: 0
Study 38519055 — intervention group
Group type: EXPERIMENTAL
Intervention: Odronextamab
Number of subjects: 0
Study 38519416 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) 40,000 IU/mL weekly infusion
Number of subjects: 101
Study 38519416 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (Control)
Number of subjects: 101
Study 38519581 — intervention group
Group type: EXPERIMENTAL
Intervention: MAG-EPA (3g daily for 7 weeks)
Number of subjects: 130
Study 38519581 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3g daily for 7 weeks)
Number of subjects: 130
Study 38519913 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg every 3 weeks until progression or unmanageable toxicity, combined with SBRT (45 Gy in 3 fractions)
Number of subjects: 60
Study 38519913 — intervention group
Group type: EXPERIMENTAL
Intervention: SBRT delivered concurrently with atezolizumab
Number of subjects: 60
Study 38519921 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 admissions in London
Number of subjects: 337029
Study 38519921 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 admissions in North-west region
Number of subjects: 337029
Study 38519921 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 admissions in South-west region
Number of subjects: 337029
Study 38519921 — intervention group
Group type: COMPARATOR
Intervention: Odds of death in regions compared to London
Number of subjects: 337029
Study 38519921 — intervention group
Group type: EXPERIMENTAL
Intervention: AKI incidence
Number of subjects: 337029
Study 38519921 — intervention group
Group type: COMPARATOR
Intervention: Odds of developing AKI compared to London
Number of subjects: 337029
Study 38519921 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with higher odds of death
Number of subjects: 337029
Study 38519921 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with higher odds of developing AKI
Number of subjects: 337029
Study 38519937 — intervention group
Group type: EXPERIMENTAL
Intervention: Z-scrotoplasty
Number of subjects: 40
Study 38519937 — intervention group
Group type: COMPARATOR
Intervention: Heineke-Mikulicz scrotoplasty
Number of subjects: 40
Study 38519968 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated plasma volume status (ePVS) calculated using the Duarte formula.
Number of subjects: 405
Study 38519968 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative ePVS derived from the Duarte formulas.
Number of subjects: 405
Study 38519982 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator (ICD) implantation
Number of subjects: 3889
Study 38519982 — intervention group
Group type: COMPARATOR
Intervention: No ICD implantation (control)
Number of subjects: 3889
Study 38519983 — intervention group
Group type: EXPERIMENTAL
Intervention: Health behavioural counselling based on the 5A's model, telephone follow-up (4 and 8 weeks), monitoring of physical activity
Number of subjects: 40
Study 38519983 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 40
Study 38519988 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab added to standard of care (SOC) maintenance treatment, n = 25
Number of subjects: 50
Study 38519988 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) alone, n = 25
Number of subjects: 50
Study 38519988 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab added to SOC
Number of subjects: 50
Study 38519988 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) alone
Number of subjects: 50
Study 38520001 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle damaging exercise in hypoxia (HYP)
Number of subjects: 0
Study 38520001 — intervention group
Group type: COMPARATOR
Intervention: Normoxia (CON)
Number of subjects: 0
Study 38520030 — intervention group
Group type: EXPERIMENTAL
Intervention: PATH intervention (peer navigation program + mHealth web application)
Number of subjects: 375
Study 38520030 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Ryan White Program case management services)
Number of subjects: 375
Study 38520055 — intervention group
Group type: EXPERIMENTAL
Intervention: home-based, remotely supported and supervised exercise training program
Number of subjects: 24
Study 38520055 — intervention group
Group type: COMPARATOR
Intervention: attention/contact wellness control
Number of subjects: 24
Study 38520420 — intervention group
Group type: EXPERIMENTAL
Intervention: Glasses with green lenses
Number of subjects: 128
Study 38520420 — intervention group
Group type: COMPARATOR
Intervention: Glasses with clear lenses (control)
Number of subjects: 128
Study 38520501 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine (5-20 mg)
Number of subjects: 200
Study 38520501 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 38520670 — intervention group
Group type: EXPERIMENTAL
Intervention: Pepinemab (20 mg/kg) administered intravenously on Days 1 and 15 of a 28-day cycle
Number of subjects: 0
Study 38520712 — intervention group
Group type: EXPERIMENTAL
Intervention: NMR-based risk score (NRS) combining lipoprotein subfractions and metabolic biomarkers relevant to NPC
Number of subjects: 446
Study 38520712 — intervention group
Group type: EXPERIMENTAL
Intervention: Small, dense very low density lipoprotein particles (VLDL-5)
Number of subjects: 446
Study 38520712 — intervention group
Group type: EXPERIMENTAL
Intervention: Large, buoyant low density lipoprotein particles (LDL-1)
Number of subjects: 446
Study 38520745 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 189
Study 38520745 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib
Number of subjects: 189
Study 38520745 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib
Number of subjects: 189
Study 38521086 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab-chemoradiotherapy
Number of subjects: 1060
Study 38521086 — intervention group
Group type: COMPARATOR
Intervention: Placebo-chemoradiotherapy
Number of subjects: 1060
Study 38521132 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily radiation therapy (66 Gy/33 fractions/6.5 weeks)
Number of subjects: 547
Study 38521132 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily radiation therapy (45 Gy/30 fractions/3 weeks)
Number of subjects: 547
Study 38521191 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (65.7 mg ferrous fumarate)
Number of subjects: 82
Study 38521191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 38521526 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-sectional household survey
Number of subjects: 4500
Study 38521526 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire interview, physical examination, and haemoglobin point-of-care testing
Number of subjects: 4500
Study 38521526 — intervention group
Group type: EXPERIMENTAL
Intervention: Probability-proportional-to-size sampling and simple random sampling
Number of subjects: 4500
Study 38521524 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored anticoagulant treatment based on individualised assessment of rVTE and major bleeding risks after 3 months of therapy.
Number of subjects: 1600
Study 38521524 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of anticoagulant treatment for patients with high rVTE and low bleeding risk.
Number of subjects: 1600
Study 38521524 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of anticoagulant treatment for patients with low rVTE risk after 3 months.
Number of subjects: 1600
Study 38521533 — intervention group
Group type: COMPARATOR
Intervention: Gonadotropin-releasing hormone antagonist given once daily from day 6 of ovarian stimulation till the day of the ovulation trigger.
Number of subjects: 400
Study 38521533 — intervention group
Group type: EXPERIMENTAL
Intervention: Dydrogesterone from the first day of ovarian stimulation till the day of ovulation trigger.
Number of subjects: 400
Study 38521535 — intervention group
Group type: EXPERIMENTAL
Intervention: Return of participant-level data to parents via a coordinator
Number of subjects: 19
Study 38521535 — intervention group
Group type: EXPERIMENTAL
Intervention: Prereturn surveys
Number of subjects: 19
Study 38521535 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey of physician site investigators
Number of subjects: 19
Study 38521641 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric assessment and management (GA + M)
Number of subjects: 168
Study 38521641 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote symptom monitoring (RSM)
Number of subjects: 168
Study 38521641 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric assessment and management plus remote symptom monitoring
Number of subjects: 168
Study 38521641 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 168
Study 38521641 — intervention group
Group type: EXPERIMENTAL
Intervention: GA + M and RSM
Number of subjects: 168
Study 38521641 — intervention group
Group type: EXPERIMENTAL
Intervention: Process evaluation outcomes
Number of subjects: 168
Study 38521736 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 72
Study 38521874 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab (IXE)
Number of subjects: 0
Study 38521883 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose tafamidis (80/61 mg po qd)
Number of subjects: 10
Study 38521893 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg iberdomide
Number of subjects: 0
Study 38521925 — intervention group
Group type: EXPERIMENTAL
Intervention: Chrononutrition Profile Questionnaire-Pregnancy (CPQ-P)
Number of subjects: 399
Study 38521931 — intervention group
Group type: EXPERIMENTAL
Intervention: Produce prescription program (intervention)
Number of subjects: 0
Study 38521946 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal velocity-intent resistance training (MI, n=10)
Number of subjects: 20
Study 38521946 — intervention group
Group type: COMPARATOR
Intervention: Controlled-tempo resistance training (CT, n=10)
Number of subjects: 20
Study 38522094 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized RHtyper using whole-exome sequencing (WES) data
Number of subjects: 3426
Study 38522127 — intervention group
Group type: EXPERIMENTAL
Intervention: Child group format
Number of subjects: 701
Study 38522127 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended format with group sessions and automated web-based sessions
Number of subjects: 701
Study 38522127 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based parental involvement
Number of subjects: 701
Study 38522127 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational brochure parental involvement
Number of subjects: 701
Study 38522127 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement Feedback System (MFS) on
Number of subjects: 701
Study 38522127 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement Feedback System (MFS) off
Number of subjects: 701
Study 38522127 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention overall
Number of subjects: 701
Study 38522170 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive Writing (EW)
Number of subjects: 58
Study 38522170 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 58
Study 38522420 — intervention group
Group type: EXPERIMENTAL
Intervention: First-trimester anatomy ultrasound
Number of subjects: 128
Study 38522443 — intervention group
Group type: EXPERIMENTAL
Intervention: Bubble continuous positive airway pressure (bCPAP)
Number of subjects: 1240
Study 38522443 — intervention group
Group type: COMPARATOR
Intervention: Low-flow oxygen therapy
Number of subjects: 1240
Study 38522503 — intervention group
Group type: EXPERIMENTAL
Intervention: Low serum antimüllerian hormone (AMH) concentration
Number of subjects: 400
Study 38522503 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 400
Study 38522597 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT)
Number of subjects: 64
Study 38523000 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity statins and ezetimibe; 92% of patients
Number of subjects: 39
Study 38523000 — intervention group
Group type: EXPERIMENTAL
Intervention: PCSK9 inhibitors (PCSK9i); 28% of patients
Number of subjects: 39
Study 38523000 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomitapide; 26% of patients
Number of subjects: 39
Study 38523000 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipoprotein-apheresis; 23% of patients
Number of subjects: 39
Study 38523000 — intervention group
Group type: EXPERIMENTAL
Intervention: Null/null variants
Number of subjects: 39
Study 38523000 — intervention group
Group type: EXPERIMENTAL
Intervention: Defective variant
Number of subjects: 39
Study 38523000 — intervention group
Group type: EXPERIMENTAL
Intervention: ASCVD events
Number of subjects: 39
Study 38523000 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic valve disease
Number of subjects: 39
Study 38523332 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen (two doses from three consecutively manufactured lots)
Number of subjects: 0
Study 38523332 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV booster
Number of subjects: 0
Study 38523332 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two doses)
Number of subjects: 0
Study 38523487 — intervention group
Group type: EXPERIMENTAL
Intervention: Tozorakimab
Number of subjects: 0
Study 38523487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38523669 — intervention group
Group type: EXPERIMENTAL
Intervention: Food allergies (peanut, tree nuts, egg, milk)
Number of subjects: 5587
Study 38523669 — intervention group
Group type: EXPERIMENTAL
Intervention: Food allergies
Number of subjects: 5587
Study 38523669 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple food allergies
Number of subjects: 5587
Study 38523669 — intervention group
Group type: EXPERIMENTAL
Intervention: Adults vs pediatric patients
Number of subjects: 5587
Study 38523907 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-module music therapy group (rhythm-guided walking and singing training)
Number of subjects: 75
Study 38523907 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm-guided walking group (music tempo-guided walking)
Number of subjects: 75
Study 38523907 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (no rehabilitation interventions)
Number of subjects: 75
Study 38523907 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-module music therapy group
Number of subjects: 75
Study 38523907 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm-guided walking group
Number of subjects: 75
Study 38524210 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous exercise (75 minutes per week for 8 weeks)
Number of subjects: 36
Study 38524210 — intervention group
Group type: COMPARATOR
Intervention: Moderate exercise (150 minutes per week for 8 weeks)
Number of subjects: 36
Study 38524210 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous exercise
Number of subjects: 36
Study 38524210 — intervention group
Group type: COMPARATOR
Intervention: Moderate exercise
Number of subjects: 36
Study 38524255 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarkers of myocardial injury or dysfunction (high sensitivity troponin and N-terminal pro B-type natriuretic peptide) measured at recruitment and follow-up
Number of subjects: 69
Study 38524255 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic inflammation biomarkers (C-reactive protein, IL-1β, IL-6, IL-10, and tumor necrosis factor alpha) measured at recruitment and follow-up
Number of subjects: 69
Study 38524255 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular magnetic resonance substudy performed at follow-up in 35 patients
Number of subjects: 69
Study 38524266 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative clinical hypnosis (CH)
Number of subjects: 92
Study 38524266 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual group (TAU)
Number of subjects: 92
Study 38524688 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive sacroiliac posterior fusion LinQ allograft implant
Number of subjects: 159
Study 38524849 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythrocyte glycocalyx sensitivity to sodium (eGCSS) in salt-sensitive females
Number of subjects: 117
Study 38524849 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythrocyte glycocalyx sensitivity to sodium (eGCSS)
Number of subjects: 117
Study 38524849 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate pressor response to oral salt (IPROS)
Number of subjects: 117
Study 38524891 — intervention group
Group type: EXPERIMENTAL
Intervention: Affected limb after meniscectomy
Number of subjects: 30
Study 38524891 — intervention group
Group type: COMPARATOR
Intervention: Contralateral limb
Number of subjects: 30
Study 38524891 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals
Number of subjects: 30
Study 38524902 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of metastases
Number of subjects: 124
Study 38524902 — intervention group
Group type: EXPERIMENTAL
Intervention: Young age
Number of subjects: 124
Study 38524902 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 124
Study 38524902 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor volume and type of local therapy modality
Number of subjects: 124
Study 38525605 — intervention group
Group type: EXPERIMENTAL
Intervention: MRA treatment
Number of subjects: 840
Study 38525605 — intervention group
Group type: COMPARATOR
Intervention: Non-MRA treatment
Number of subjects: 840
Study 38525609 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT-derived VFR
Number of subjects: 224
Study 38525699 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-Implemented Music Therapy intervention (structured over five weeks with ten 1-hour sessions, twice weekly)
Number of subjects: 0
Study 38525699 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-Implemented Music Therapy intervention
Number of subjects: 0
Study 38525752 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention not specified
Number of subjects: 0
Study 38525752 — intervention group
Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 0
Study 38525782 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring via a smartphone app
Number of subjects: 0
Study 38525782 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional follow-up)
Number of subjects: 0
Study 38526047 — intervention group
Group type: EXPERIMENTAL
Intervention: AT-752 single dose up to 1,500 mg
Number of subjects: 0
Study 38526047 — intervention group
Group type: EXPERIMENTAL
Intervention: AT-752 multiple doses up to 750 mg three times daily (TID)
Number of subjects: 0